Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Korean J Hematol. 2011 Mar;46(1):45-48. English. Case Report. https://doi.org/10.5045/kjh.2011.46.1.45
Hong MJ , Lee HG , Hur M , Kim SY , Cho YH , Yoon SY .
Division of Hematology-Oncology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. mlee@kuh.ac.kr
Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
Abstract

Thrombotic thrombocytopenic purpura (TTP) is a critical complication of treatment with mitomycin C. We retrospectively describe the case of a patient with progressive renal cell carcinoma and mitomycin-induced TTP refractory to plasma exchange and glucocorticoids; we describe the clinical course, successful management of TTP with rituximab, and follow-up of this case. Mitomycin-induced TTP resolved completely by a total of 4 infusions of rituximab 375 mg/m2 on a weekly basis, and it took up to 12 months to obtain a platelet count of >100,000/microL. Rituximab is indicated for the treatment of mitomycin-induced TTP refractory to plasma exchange and glucocorticoids, and it could improve the patient's quality of life despite the presence of underlying malignancy.

Copyright © 2019. Korean Association of Medical Journal Editors.